Desmopressin (DDAVP)

Platelets

Volumn , Issue , 2007, Pages 1237-1249

  Mannucci, Pier Mannuccio ^a   Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249796249     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50829-6     Document Type: Chapter

References (149)

1. Mannucci P.M. Desmopressin: A nontransfusional agent. Annu Rev Med 1990, 41:55-64.
2. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997, 90:2515-2521.
3. Mannucci P.M., Ruggeri Z.M., Pareti F.I., et al. 1-Deamino-8-d-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet 1977, 1:869-872.
4. Mannucci P.M. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 1986, 8:19-45.
5. Mannucci P.M., Canciani M.T., Rota L., et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand's disease. Br J Haematol 1981, 47:283-293.
6. Cash J.D., Gader A.M.A., de Costa J. The release of plasminogen activator and factor VIII by LVP, AVP and DDAVP, ATIII, and OT in man. Br J Haematol 1974, 27:363-364.
7. Mannucci P.M., Aberg M., Nilsson I.M., et al. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975, 30:81-93.
8. Levi M., de Boer J.P., Roem D., et al. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992, 67:111-116.
9. Warrier L., Lusher J.M. DDAVP: A useful alternative to blood components in moderate hemophilia A and von Willebrand's disease. J Pediatr 1983, 102:228-233.
10. Mariani G., Ciavarella N., Mazzucconi M.G., et al. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand's disease. A study of 43 patients. Clin Lab Hematol 1984, 6:229-238.
11. de la Fuente B., Kasper C.K., Rickles F.R., et al. Response of patients with mild and moderate hemophilia A and von Willebrand disease to treatment with desmopressin. Ann Intern Med 1985, 103:6-14.
12. Mannucci P.M., Bettega D., Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992, 82:87-93.
13. Ruggeri Z.M., Mannucci P.M., Lombardi R., et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982, 58:1272-1278.
14. Federici A.B., Mazurier C., Berntorp E., et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004, 103:2032-2038.
15. Rose E.H., Aledort L.M. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1993, 114:563-568.
16. Lethagen S., Ragnarson U., Tennvall G. Selftreatment with desmopressin intranasal spray in patients with bleeding disorders: Effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993, 66:257-260.
17. Rodeghiero F., Castaman G., Mannucci P.M. Prospective multicenter study of subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996, 76:692-696.
18. Federici A.B., Rand J.H., Bucciarelli P., et al. Acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost 2000, 84:345-349.
19. Federici A.B., Stabile F., Castaman G., et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches. Blood 1998, 92:2707-2711.
20. Kobrinsky N.L., Israels E.D., Gerrard J.M., et al. Shortening of bleeding time by 1-deamino-8-d-arginine vasopressin in various bleeding disorders. Lancet 1984, 1:1145-1148.
21. Kohler M., Hellstern P., Morgenstern E., et al. Gray platelet syndrome: Selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover. Blut 1985, 50:331-340.
22. Mannucci P.M., Vicente V., Vianello L., et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986, 67:1148-1153.
23. De Marco L., Girolami A., Zimmerman T.S., et al. von Willebrand factor interaction with the glycoprotein IIb/ IIIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986, 77:1272-1277.
24. Pfueller S.L., Howard M.A., White J.G., et al. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome. Thromb Haemost 1987, 58:1060-1063.
25. Schulman S., Johnsson H., Egberg N., et al. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 1987, 45:165-174.
26. Kentro T.B., Lottenberg R., Kitchens C.S. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol 1987, 24:215-219.
27. Sieber P.R., Belis J.A., Jarowenko M.V., et al. Desmopressin control of surgical hemorrhage secondary to prolonged bleeding time. J Urol 1988, 139:1066-1067.
28. Cuthbert R.J., Watson H.H., Handa S.I., et al. DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Res 1988, 49:649-650.
29. Nieuwenhuis H.K., Sixma J.J. 1-Desamino-8-d-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency. Ann Intern Med 1988, 108:65-67.
30. Kim H.C., Salva K., Fallot P.L., et al. Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin. Thromb Haemost 1988, 59:221-224.
31. Wijermans P.W., van Dorp D.B. Hermansky-Pudlak syndrome: Correction of bleeding time by 1-desamino-8d-arginine vasopressin. Am J Hematol 1989, 30:154-157.
32. Van Dorp D.B., Wijermans P.W., Meire F., et al. The Hermansky-Pudlak syndrome. Variable reaction to 1-desamino-8d-arginine vasopressin for correction of the bleeding time. Ophthalmic Paediatr Genet 1990, 11:237-244.
33. Di Michele D.M., Hathaway W.E. Use of DDAVP in inherited and acquired platelet dysfunctions. Am J Hematol 1990, 33:39-45.
34. Waldenstrom E., Holmberg L., Axelsson U., et al. Bernard-Soulier syndrome in two Swedish families: Effect of DDAVP on bleeding time. Eur J Haematol 1991, 46:182-187.
35. Castaman G., Rodeghiero F. Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia. Thromb Res 1992, 68:309-315.
36. Castaman G., Rodeghiero F. Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. Thromb Res 1993, 69:407-412.
37. Greinacher A., Potzsch B., Kiefel V., et al. Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von Willebrand-factor. Ann Hematol 1993, 67:149-150.
38. Lekas M.D., Crowley J.P. Easy bruisability, aspirin intolerance, and response to DDAVP. Laryngoscope 1993, 103:156-159.
39. Prinsley P., Wood M., Lee C.A. Adenotonsillectomy in patients with inherited bleeding disorders. Clin Otolaryngol 1993, 18:206-208.
40. Kemahli S., Canatan D., Uysal Z., et al. DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Haemost 1994, 71:675.
41. Cattaneo M., Zighetti M.L., Lombardi R., et al. Role of ADP in platelet aggregation at high shear: Studies in a patient with congenital defect of platelet responses to ADP. Br J Haematol 1994, 88:826-829.
42. Rao A.K., Ghosh S., Sun L., et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebocontrolled trial. Thromb Haemost 1995, 74:1071-1078.
43. Cattaneo M., Pareti F.I., Zighetti M., et al. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: Correlation with the bleeding time. J Lab Clin Med 1995, 125:540-547.
44. Noris P., Arbustini E., Spedini P., et al. A new variant of Bernard-Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. Br J Haematol 1998, 103:1004-1013.
45. Cattaneo M., Lecchi A., Agati B., et al. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999, 96:213-217.
46. Zatik J., Poka R., Borsos A., et al. Variable response of Hermansky-Pudlak syndrome to prophylactic administration of 1-desamino-8d-arginine in subsequent pregnancies. Eur J Obstet Gynecol Reprod Biol 2002, 104:165-166.
47. Fuse I., Higuchi W., Mito M., et al. DDAVP normalized the bleeding time in patients with congenital platelet TxA2 receptor abnormality. Transfusion 2003, 43:563-567.
48. Fuse I., Higuchi W., Aizawa Y. 1-deamino-8-darginine vasopressin (DDAVP) normalized the bleeding time in patients with platelet disorder characterized by defective calcium ionophore-induced platelet aggregation. Br J Haematol 2003, 122:870-871.
49. Cordova A., Barrios N.J., Ortiz I., et al. Poor response to desmopressin acetate (DDAVP) in children with Hermansky-Pudlak syndrome. Pediatr Blood Cancer 2005, 44:51-54.
50. Sehbai A.S., Abraham J., Brown V.K., et al. Perioperative management of a patient with May-Hegglin anomaly requiring craniotomy. Am J Hematol 2005, 79:303-308.
51. Janson P.A., Jubelirer S.J., Weinstein M.S., et al. Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980, 303:1318-1321.
52. Watson A.J., Keogh J.A. 1-Deamino-8-darginine vasopressin as a therapy for the bleeding diathesis of renal failure. Am J Nephrol 1984, 4:49-51.
53. Mannucci P.M., Remuzzi G., Pusineri F., et al. Deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983, 308:8-12.
54. Viganò G.L., Mannucci P.M., Lattuada A., et al. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 1989, 31:32-35.
55. Shapiro M.D., Kelleher S.P. Intranasal deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. Am J Nephrol 1984, 4:260-261.
56. Rydzewski A., Rowinski M., Mysliwiec M. Shortening of bleeding time after intranasal administration of 1-deamino-8-d-arginine vasopressin to patients with chronic uremia. Folia Haematol Int Mag Klin Morphol Blutforsch 1986, 113:823-830.
57. Canavese C., Salomone M., Pacitti A., et al. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet 1985, 1:867-868.
58. Gotti E., Mecca G., Valentino C., et al. Renal biopsy in patients with acute renal failure and prolonged bleeding time. Lancet 1984, 978-979.
59. Watson A.J., Keogh J.A. Effect of 1-deamino-8-d-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 1982, 32:49-52.
60. Gotti E., Mecca G., Valentino C., et al. Renal biopsy in patients with acute renal failure and prolonged bleeding time: A preliminary report. Am J Kidney Dis 1985, 6:397-399.
61. Buckley D.J., Barrett A.P., Koutts J., et al. Control of bleeding in severely uremic patients undergoing oral surgery. Oral Surg Oral Med Oral Pathol 1986, 61:546-549.
62. Juhl A., Jorgensen F. DDAVP and lifethreatening diffuse gastric bleeding in uraemia. Case report. Acta Chir Scand 1987, 153:75-77.
63. Donovan K.L., Moore R.H., Mulkerrin E., et al. An audit of appropriate tests in renal biopsy coagulation screens. Am J Kidney Dis 1992, 19:335-338.
64. Sateriale M., Cronan J.J., Savadler L.D. A 5-year experience with 307 CT-guided renal biopsies: Results and complications. J Vasc Interv Radiol 1991, 2:401-407.
65. Livio M., Mannucci P.M., Viganò G., et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986, 315:731-735.
66. Moia M., Mannucci P.M., Vizzotto L., et al. Improvement in the hemostatic defect of uremia after treatment with recombinant human erythropoietin. Lancet 1987, 2:1227-1229.
67. Burroughs A.K., Matthews K., Qadiri M., et al. Desmopressin and bleeding time in patients with cirrhosis. Br J Med 1985, 291:1377-1381.
68. Lopez P., Otaso J.C., Alvarez D., et al. Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis. Acta Gastroenterol Latinoam 1997, 27:59-62.
69. Cattaneo M., Tenconi P.M., Alberca I., et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990, 64:358-360.
70. de Franchis F., Arcidiacono P.G., Carpinelli P.G., et al. Randomized controlled trial of desmopressin plus terlipressin and terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double blind study. Hepatology 1993, 18:1102-1107.
71. Parker R.I., Grewal R.P., McKeown L.P., et al. Effect of platelet count on the DDAVP-induced shortening of the bleeding time in thrombocytopenic Gaucher's patients. Am J Pediatr Hematol Oncol 1992, 14:39-43.
72. Castaman G., Bona E.D., Schiavotto C., et al. Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. Haematologica 1997, 82:584-587.
73. Cattaneo M., Lombardi R., Bettega D., et al. Shearinduced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993, 13:393-397.
74. Schulman S., Johnsson H. Heparin, DDAVP and the bleeding time. Thromb Hemost 1991, 65:242-244.
75. Johnstone M.T., Andrews T., Ware J.A., et al. Bleeding time prolongation with streptokinase and its reduction with 1-deamino-8-d-arginine vasopressin. Circulation 1990, 82:2142-2151.
76. Bove C.M., Casey B., Marder V.J. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 1996, 75:471-475.
77. Reiter R.A., Mayr F., Blazicek H., et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003, 102:4594-4599.
78. Chard R.B., Kam C.A., Nunn G.R., et al. Use of desmopressin in the management of aspirin-related and intractable haemorrhage after cardiopulmonary bypass. Aust N Z J Surg 1990, 60:125-128.
79. Kam P.C. Use of desmopressin (DDAVP) in controlling aspirin-induced coagulopathy after cardiac surgery. Heart Lung 1994, 23:333-336.
80. Stine K.C., Becton D.L. DDAVP therapy controls bleeding in Ehlers-Danlos syndrome. J Pediatr Hematol Oncol 1997, 19:156-158.
81. Quitt M., Froom P., Veisler A., et al. The effect of desmopressin on massive gastrointestinal bleeding in hereditary telangiectasia unresponsive to treatment with cryoprecipitate. Arch Intern Med 1990, 150:1744-1746.
82. Baldree L.A., Ault B.H., Chesney C.M., et al. Intravenous desmopressin acetate in children with sickle trait and persistent macroscopic hematuria. Pediatrics 1990, 86:238-243.
83. Moudgil A., Kamil E.S. Protracted, gross hematuria in sickle cell trait: Response to multiple doses of 1-desamino-8-d-arginine vasopressin. Pediatr Nephrol 1996, 10:210-212.
84. Salzman E.W., Weinstein M.J., Weintraub R.M., et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986, 314:1402-1406.
85. Rocha E., Llorens R., Paramo J.A., et al. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?. Circulation 1988, 77:1319-1323.
86. Hackmann T., Gascoyne R.D., Naiman S.C., et al. A trial of desmopressin (1-desamino-8-d-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989, 321:1437-1443.
87. Seear M.D., Wadsworth L.D., Rogers P.C., et al. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1989, 98:217-219.
88. Lazenby W.D., Russo I., Zadeh B.J., et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990, 82:IV413-IV419.
89. Andersson T.L., Solem J.O., Tengborn L., et al. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990, 81:872-878.
90. Hedderich G.S., Petsikas D.J., Cooper B.A., et al. Desmopressin acetate in uncomplicated coronary artery bypass surgery: A prospective randomized clinical trial. Can J Surg 1990, 33:33-36.
91. Reich D.L., Hammerschlag B.C., Rand J.H., et al. Desmopressin acetate is a mild vasodilator that does not reduce blood loss in uncomplicated cardiac surgical procedures. J Cardiothorac Vasc Anesth 1991, 5:142-145.
92. Horrow J.C., van Riper D.F., Strong M.D., et al. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991, 84:2063-2070.
93. Gratz I., Koehler J., Olsen D., et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992, 104:1417-1422.
94. de Prost D., Barbier-Boehm G., Hazebroucq J., et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992, 68:106-110.
95. Ansell J., Klassen V., Lew R., et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg 1992, 104:117-123.
96. Mongan P.D., Hosking M.P. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992, 77:38-46.
97. Marquez J., Koehler S., Strelec S.R., et al. Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: A prospective, blinded, randomized study. J Cardiothorac Vasc Anesth 1992, 6:674-676.
98. Dilthey G., Dietrich W., Spannagl M., et al. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993, 7:425-430.
99. Reynolds L.M., Nicolson S.C., Jobes D.R., et al. Desmopressin does not decrease bleeding after cardiac operation in young children. J Thorac Cardiovasc Surg 1993, 106:954-958.
100. Rocha E., Hidalgo F., Llorens R., et al. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994, 90:921-927.
101. Sheridan D.P., Card R.T., Pinilla J.C., et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994, 37:33-36.
102. Temeck B.K., Bachenheimer L.C., Katz N.M., et al. Desmopressin acetate in cardiac surgery: A doubleblind, randomized study. South Med J 1994, 87:611-615.
103. Casas J.I., Zuazu-Jausoro I., Mateo J., et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebocontrolled study. J Thorac Cardiovasc Surg 1995, 110:1107-1117.
104. Despotis G.J., Levine V., Saleem R., et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: A randomised controlled trial. Lancet 1999, 354:106-110.
105. Oliver W.C., Santrach P.J., Danielson G.K., et al. Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann Thorac Surg 2000, 70:1923-1930.
106. Cattaneo M., Harris A.S., Stromberg U., et al. The effect of desmopressin on reducing blood loss in cardiac surgery -A meta-analysis of double-blind, placebocontrolled trials. Thromb Haemost 1995, 74:1064-1070.
107. Fremes S.E., Wong B.I., Lee E., et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994, 58:1580-1588.
108. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 1999, 354:1940-1947.
109. Kobrinsky N.L., Letts R.M., Patel L.R., et al. 1-Desamino-8-d-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 1987, 107:446-450.
110. Guay J., Rainberg C., Poitras B, et al. A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis. Anesth Analg 1992, 75:405-410.
111. Theroux M.C., Corddry D.H., Tietz A.E., et al. A study of desmopressin and blood loss during spinal fusion for neuromuscular scoliosis: A randomized, controlled, double-blinded study. Anesthesiology 1997, 87:260-267.
112. Alanay A., Acaroglu E., Ozdemir O., et al. Effects of deamino-8-d-arginin vasopressin on blood loss and coagulation factors in scoliosis surgery. A double-blind randomized clinical trial. Spine 1999, 24:877-882.
113. Flordal P.A., Ljungstrom K.G., Ekman B., et al. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand 1992, 63:381-385.
114. Schott U., Sollen C., Axelsson K., et al. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesthesiol Scand 1995, 39:592-598.
115. Karnezis T.A., Stulberg S.D., Wixson R.L., et al. The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial. J Bone Joint Surg Am 1994, 76:1450-1545.
116. Haith L.R., Patton M.L., Goldman W.T., et al. Diminishing blood loss after operation for burns. Surg Gynaecol Obstet 1993, 176:119-123.
117. Lethagen S., Rugarn P., Bergqvist D. Blood loss and safety with desmopressin or placebo during aorto-iliac graft surgery. Eur J Vasc Surg 1991, 5:173-178.
118. Clagett G.P., Valentine R.J., Myers S.I., et al. Does desmopressin improve hemostasis and reduce blood loss from aortic surgery? A randomized, double-blind study. J Vasc Surg 1995, 22:223-229.
119. Smith .J., Gill J.C., Ambruso D.R., et al. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989, 31:199-202.
120. Bertholini D.M., Butler C.S. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. Anaesth Intens Care 2000, 28:199-201.
121. Cohen A.J., Kessler C.M., Ewenstein B.M. Management of von Willebrand disease: A survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001, 7:235-241.
122. Kujovich J.L. Von Willebrand disease and pregnancy. J Thromb Haemost 2005, 3:246-253.
123. Ray J.G. DDAVP use during pregnancy: An analysis of its safety for mother and child. Obstet Gynecol Surv 1998, 53:450-455.
124. Mannucci P.M. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005, 105:3382.
125. Mannucci P.M., Carlsson S., Harris A.S. Desmopressin, surgery and thrombosis. Thromb Haemost 1994, 71:154-155.
126. Kanwar S., Woodman R.C., Poon M.C., et al. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood 1995, 86:2760-2766.
127. Takeuchi M., Naguza H., Kanedu T. DDAVP and epinephrine induce changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood 1988, 72:850-854.
128. Booyse E.M., Osikowicz G., Fedr S. Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Thromb Haemost 1981, 46:668.
129. Kaufmann J.E., Oksche A., Wollheim C.B., et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000, 106:107-116.
130. Cattaneo M., Simoni L., Gringeri A., et al. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: Evidence that the DDAVPinduced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. Br J Haematol 1994, 86:333-337.
131. Kaufmann J.E., Vischer U.M. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemostas 2003, 1:682-689.
132. Xu L., Nichols T.C., Sarkar R., et al. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA 2005, 102:6080-6085.
133. Lamont P.A, Ragni M.V. Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation. J Thromb Haemost 2005, 3:2259-2263.
134. Sakariassen K.S., Cattaneo M., van den Berg A., et al. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984, 64:229-236.
135. Pareti F.I., Cattaneo M., Carpinelli L., et al. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test. Thromb Haemost 1996, 76:460-468.
136. Cattaneo M., Federici A.B., Lecchi A., et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999, 82:35-39.
137. Cattaneo M., Moia M., Delle Valle P., et al. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 1989, 74:1972-1975.
138. Escolar G., Cases A., Monteagudo J., et al. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 1989, 114:36-42.
139. Lethagen S., Nilssonm I.M. DDAVP-induced enhancement of platelet retention: Its dependence on plateletvon Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 1992, 49:7-13.
140. Tsai J.-M., Sussman I.I., Nagel R.L., et al. Desmopressin induces adhesion of normal human erythrocytes to the endothelial surface of a perfused microvascular preparation. Blood 75 1990, 261-265.
141. Setty B.N., Dampier C.D., Stuart M.J. 1-Deamino-8-d-arginine vasopressin decreases the production of 13-hydroxyoctadecadienoic acid by endothelial cells. Thromb Res 1992, 67:545-558.
142. Galvez A., Gomez-Ortiz G., Diaz-Ricart M., et al. Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost 1997, 77:975-980.
143. Mannucci P.M., Ghirardini A. Desmopressin: Twenty years after. Thromb Haemost 1997, 78:958.
144. Edlund M., Blomback M., Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002, 13:225-231.
145. Kentro T.B., Lottenberg R., Kitchens C.S. Clinical efficacy of desmopressin acetate for hemosatatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol 1987, 24:215-219.
146. Sieber P.R., Belis J.A., Jarowenko M.V., et al. Desmopressin control of surgical hemorrhage secondary to prolonged bleeding time. J Urol 1988, 139:1066-1067.
147. Flordal P.A., Ljungstrom K.G., Svensson J. Desmopressin reverses effects of dextran on von Willebrand factor. Thromb Hemost 1989, 61:541.
148. Yasui H., Adachi Y., Minami T, et al. Combination therapy of DDAVP and conjugated estrogens for a recurrent large subcutaneous hematoma in Ehlers-Danlos syndrome. Am J Hematol 2003, 72:71-72.
149. Nacul F.E., de Moraes E., Penido C., et al. Massive nasal bleeding and hemodynamic instability associated with clopidogrel. Pharm World Sci 2004, 26:6-7.